Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series

EGFR is frequently mutated in non-small-cell lung carcinomas (NSCLCs). Clinically available tyrosine kinase inhibitors (TKIs) are effective in treating EGFR-mutant NSCLC. In this case series, we present five patients with TKI-treated EGFR-mutated NSCLC who developed leptomeningeal disease (LMD) lack...

Повний опис

Бібліографічні деталі

Автори:	Ugur Sener, Nassim Matin, Helena Yu, Andrew Lin, T Jonathan Yang, Rachna Malani
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Taylor & Francis Group 2019-12-01
Серія:	CNS Oncology
Предмети:	EGFR leptomeningeal disease NSCLC targeted therapy tumor imaging tyrosine kinase inhibitors
Онлайн доступ:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0010
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!